Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Funding will support research on conditions including fatty liver disease, liver cancer, asthma and chronic kidney disease.
Trial will assess antibody response in people who did not respond to two-dose regimen.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
This is according to an analysis of a large group of veterans.
Jackie Johnson was diagnosed with hepatitis C in 2010. But in 2015, he took advantage of the latest hep C treatments and was soon cured.
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
This finding held true even when the researchers restricted their analysis to caffeine from soft drinks.
Zepatier (grazoprevir/elbasvir) is approved to treat those with genotypes 1 and 4 of hepatitis C virus.
Cure rates were near 100 percent even though the population in the study’s analysis had high rates of other health conditions.
March is National Kidney Month, and an opportune time to look at hepatitis C and the kidneys.
Among the hep C population, other factors associated with chronic kidney disease include being older and having diabetes or HIV.
This is according to a large study of Swedish people with hep C and chronic kidney disease.
And can treating the virus reduce the risk of chronic kidney and cardiovascular diseases as well as the risk of death from such causes?
Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.
One research team has broken down the risk and benefits associated with treating more people in eight weeks or fewer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.